Actuate Therapeutics, Inc (ACTU) Total Debt to Capital

Actuate Therapeutics, Inc. (ACTU) is a biopharmaceutical business developing low-toxicity drugs for metastasis therapy protected by global patents. This chart of the stock price reflects the separate_debt_total_eq metric at 0.42. The development of unique inhibitors promises pricing power following FDA approval. However, the sector is characterized by high financial expenditures and significant risks of failure during clinical trials.

This indicator reflects the degree of business dependence on borrowed funds relative to its net assets. For Actuate Therapeutics, Inc. (ACTU), which invests in the development of solid tumor therapies, the debt-to-equity ratio demonstrates the cost of financing oncology research. An upward trend in the curve signals an increase in the debt load on equity. A stable metric level confirms financial stability during expansion into biopharmaceutical markets.